Spark Therapeutics, Inc. (NASDAQ:ONCE) – Cantor Fitzgerald lifted their FY2018 earnings per share (EPS) estimates for shares of Spark Therapeutics in a report issued on Sunday. Cantor Fitzgerald analyst E. Piros now expects that the biotechnology company will post earnings per share of ($5.14) for the year, up from their previous estimate of ($5.54). Cantor Fitzgerald has a “Buy” rating and a $94.00 price objective on the stock.
ONCE has been the subject of a number of other reports. Jefferies Group LLC began coverage on Spark Therapeutics in a research report on Monday, July 10th. They issued a “buy” rating and a $85.00 price objective for the company. Cowen and Company reiterated a “buy” rating and issued a $95.00 price objective on shares of Spark Therapeutics in a research report on Tuesday, October 10th. BidaskClub upgraded Spark Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Barclays PLC lifted their price objective on Spark Therapeutics from $104.00 to $107.00 and gave the stock an “overweight” rating in a research report on Friday, October 13th. Finally, Chardan Capital reiterated a “buy” rating and issued a $100.00 price objective on shares of Spark Therapeutics in a research report on Friday, October 13th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and eighteen have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $90.47.
Spark Therapeutics (NASDAQ ONCE) traded down 1.78% during trading on Wednesday, hitting $81.49. 203,481 shares of the stock traded hands. The stock’s market cap is $2.55 billion. The firm’s 50-day moving average is $85.85 and its 200 day moving average is $85.85. Spark Therapeutics has a 52 week low of $35.07 and a 52 week high of $91.75.
Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.75) by ($0.14). Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The business had revenue of $1.48 million for the quarter, compared to the consensus estimate of $1.33 million. During the same quarter last year, the business posted ($1.04) EPS. The business’s revenue for the quarter was up 14.7% on a year-over-year basis.
In related news, CEO Jeffrey D. Marrazzo sold 28,650 shares of the business’s stock in a transaction that occurred on Wednesday, August 2nd. The stock was sold at an average price of $80.01, for a total value of $2,292,286.50. Following the completion of the transaction, the chief executive officer now directly owns 258,650 shares in the company, valued at approximately $20,694,586.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Anand Mehra sold 211,858 shares of the business’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $70.15, for a total value of $14,861,838.70. The disclosure for this sale can be found here. Insiders sold a total of 1,333,195 shares of company stock valued at $109,070,506 over the last quarter. 7.30% of the stock is owned by insiders.
Several institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. grew its position in shares of Spark Therapeutics by 11.6% in the 2nd quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock valued at $122,689,000 after purchasing an additional 213,520 shares during the period. Vanguard Group Inc. grew its position in shares of Spark Therapeutics by 5.3% in the 2nd quarter. Vanguard Group Inc. now owns 1,924,463 shares of the biotechnology company’s stock valued at $114,968,000 after purchasing an additional 96,803 shares during the period. JPMorgan Chase & Co. grew its position in shares of Spark Therapeutics by 3.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,607,972 shares of the biotechnology company’s stock valued at $96,060,000 after purchasing an additional 58,879 shares during the period. Wellington Management Group LLP grew its position in shares of Spark Therapeutics by 119.5% in the 1st quarter. Wellington Management Group LLP now owns 808,782 shares of the biotechnology company’s stock valued at $43,140,000 after purchasing an additional 440,287 shares during the period. Finally, Janus Henderson Group PLC acquired a new position in shares of Spark Therapeutics in the 2nd quarter valued at approximately $30,848,000. Institutional investors and hedge funds own 77.84% of the company’s stock.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.